Your browser is no longer supported. Please, upgrade your browser.
Settings
NCNA NuCana plc daily Stock Chart
NCNA [NASD]
NuCana plc
Index- P/E- EPS (ttm)-0.78 Insider Own0.65% Shs Outstand31.88M Perf Week-5.94%
Market Cap169.30M Forward P/E- EPS next Y-0.94 Insider Trans0.00% Shs Float16.31M Perf Month-15.19%
Income-25.00M PEG- EPS next Q-0.22 Inst Own50.40% Short Float15.27% Perf Quarter3.36%
Sales- P/S- EPS this Y-53.50% Inst Trans-0.56% Short Ratio36.85 Perf Half Y-12.54%
Book/sh2.48 P/B2.11 EPS next Y-13.00% ROA-22.50% Target Price- Perf Year-46.58%
Cash/sh2.00 P/C2.61 EPS next 5Y- ROE-24.40% 52W Range3.81 - 10.94 Perf YTD-14.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-52.19% Beta-
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low37.27% ATR0.33
Employees31 Current Ratio10.50 Sales Q/Q- Oper. Margin- RSI (14)35.11 Volatility4.27% 5.76%
OptionableNo Debt/Eq0.01 EPS Q/Q-130.20% Profit Margin- Rel Volume0.58 Prev Close5.39
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume67.62K Price5.23
Recom1.50 SMA20-9.72% SMA50-10.38% SMA200-14.00% Volume38,927 Change-2.92%
Aug-19-19Initiated H.C. Wainwright Buy $20
Oct-19-18Initiated Piper Jaffray Overweight
Oct-23-17Initiated William Blair Outperform
Oct-23-17Initiated Jefferies Buy $25
Oct-23-17Initiated Citigroup Buy $23
Jul-02-20 12:25PM  
Jun-29-20 12:49PM  
Jun-16-20 10:47AM  
Jun-10-20 01:04PM  
Jun-02-20 08:59AM  
Jun-01-20 12:20PM  
May-28-20 10:54AM  
May-27-20 09:34AM  
07:00AM  
May-24-20 07:00AM  
May-19-20 04:01PM  
May-18-20 07:00AM  
May-15-20 07:00AM  
May-05-20 04:01PM  
Apr-02-20 04:01PM  
Mar-18-20 08:25AM  
Mar-11-20 08:03AM  
Mar-10-20 04:02PM  
04:01PM  
Mar-04-20 07:00AM  
Feb-29-20 07:00AM  
Feb-25-20 09:46AM  
07:00AM  
Jan-27-20 07:00AM  
Jan-03-20 10:54AM  
Dec-20-19 05:44PM  
Dec-11-19 07:04AM  
Nov-27-19 03:32AM  
Nov-26-19 07:00AM  
Nov-22-19 10:48AM  
Nov-20-19 09:50AM  
Nov-14-19 07:00AM  
Nov-13-19 04:01PM  
Oct-29-19 07:00AM  
Oct-25-19 07:00AM  
Oct-17-19 11:24AM  
Oct-16-19 12:15PM  
Sep-20-19 11:12AM  
Sep-17-19 10:44AM  
Sep-16-19 08:48AM  
Sep-10-19 06:00PM  
Sep-06-19 10:06AM  
Sep-03-19 11:00AM  
Sep-02-19 09:17AM  
Aug-29-19 08:00AM  
Aug-27-19 08:00AM  
Aug-21-19 04:01PM  
11:08AM  
Aug-20-19 11:00AM  
08:00AM  
Aug-18-19 06:25PM  
Jul-18-19 11:18AM  
Jul-17-19 07:00AM  
Jun-13-19 10:26AM  
07:44AM  
Jun-12-19 07:24PM  
May-30-19 04:01PM  
May-14-19 04:01PM  
Apr-02-19 08:00AM  
Mar-30-19 10:27AM  
Mar-18-19 06:28AM  
Mar-07-19 04:01PM  
Mar-05-19 08:00AM  
Feb-27-19 04:45PM  
Jan-25-19 08:32AM  
08:15AM  
Jan-23-19 04:01PM  
Jan-07-19 10:06AM  
Nov-28-18 04:01PM  
Nov-27-18 04:01PM  
Nov-20-18 07:00AM  
Nov-07-18 07:00AM  
Nov-01-18 07:00AM  
Oct-24-18 05:30AM  
Oct-22-18 07:00AM  
Oct-21-18 06:54AM  
Oct-09-18 01:15PM  
Aug-29-18 04:01PM  
Aug-28-18 04:01PM  
Jun-01-18 11:08AM  
May-25-18 04:01PM  
May-23-18 04:02PM  
May-21-18 07:01AM  
07:00AM  
May-17-18 07:00AM  
Apr-09-18 07:01AM  
07:00AM  
Mar-21-18 04:09PM  
Mar-02-18 08:01AM  
08:00AM  
Jan-23-18 07:00AM  
Jan-22-18 09:59AM  
Jan-19-18 12:02PM  
Nov-20-17 08:02AM  
Nov-15-17 08:01AM  
Nov-02-17 08:00AM  
Oct-23-17 02:16PM  
Oct-02-17 02:28PM  
01:40PM  
Oct-01-17 09:43AM  
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.